PMID- 15995859
OWN - NLM
STAT- MEDLINE
DCOM- 20060203
LR  - 20181113
IS  - 0342-4642 (Print)
IS  - 0342-4642 (Linking)
VI  - 31
IP  - 8
DP  - 2005 Aug
TI  - Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently 
      when combined with danaparoid sodium than with unfractionated heparin.
PG  - 1101-8
AB  - OBJECTIVE: This study investigated the potential benefits of combination therapy 
      using antithrombin (AT) with danaparoid sodium (DA) compared with the use of AT 
      with unfractionated heparin (UFH) in the treatment of sepsis. METHODS: Rats 
      infused with lipopolysaccharide were treated with either DA alone, AT alone, AT 
      plus DA, AT plus UFH, or human serum albumin as controls. AT (125 U/kg) was 
      injected into the AT group immediately after lipopolysaccharide infusion. The 
      AT/DA and AT/UFH groups received the same dose of AT in conjunction with either 
      DA (400 U/kg) or UFH (400 U/kg). The status of the mesenteric microcirculation 
      was examined by intra-vital microscopy and the laboratory indices of coagulation, 
      inflammation, and organ dysfunction were measured. RESULTS: The coagulation 
      markers were improved following the administration of DA or UFH. The decreases in 
      the WBC counts were significantly suppressed in the AT/DA group. The elevation of 
      IL-6 decreased in the AT, DA, and AT/DA groups (all p<0.01) but not in the AT/UFH 
      group. The prostaglandin I2 levels were significantly elevated only in the AT/DA 
      group (p<0.05). The WBC adhesion was significantly suppressed in the DA, AT/UFH, 
      and AT/DA groups (p<0.05), and the RBC velocity was best maintained in the AT/DA 
      group with no associated increase in capillary hemorrhage. The elevation of ALT 
      and BUN significantly improved only in the AT/DA group. ONCLUSION: Organ 
      dysfunction can thus be alleviated by even moderate doses of AT replacement when 
      co-administered with DA.
FAU - Iba, Toshiaki
AU  - Iba T
AD  - Department of Surgery, Juntendo University School of Medicine, Juntendo Urayasu 
      Hospital, 2-1-1 Tomioka, 279-0021 Urayasu, Chiba, Japan. iba-jun@umin.ac.jp
FAU - Kidokoro, Akio
AU  - Kidokoro A
FAU - Fukunaga, Masaki
AU  - Fukunaga M
FAU - Nagakari, Kunihiko
AU  - Nagakari K
FAU - Suda, Masaru
AU  - Suda M
FAU - Yoshikawa, Seiichiro
AU  - Yoshikawa S
FAU - Ida, Yukiko
AU  - Ida Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20050702
PL  - United States
TA  - Intensive Care Med
JT  - Intensive care medicine
JID - 7704851
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipopolysaccharides)
RN  - 24967-94-0 (Dermatan Sulfate)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 9005-49-6 (Heparin)
RN  - 9007-28-7 (Chondroitin Sulfates)
RN  - 9050-30-0 (Heparitin Sulfate)
RN  - BI6GY4U9CW (danaparoid)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Alanine Transaminase/blood
MH  - Animals
MH  - Anticoagulants/therapeutic use
MH  - Antithrombins/*therapeutic use
MH  - Blood Urea Nitrogen
MH  - Chondroitin Sulfates/*therapeutic use
MH  - Dermatan Sulfate/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heparin/therapeutic use
MH  - Heparitin Sulfate/*therapeutic use
MH  - Interleukin-6/blood
MH  - Leukocyte Count
MH  - Lipopolysaccharides/toxicity
MH  - Multiple Organ Failure/chemically induced/*drug therapy
MH  - Platelet Count
MH  - Rats
MH  - Rats, Wistar
EDAT- 2005/07/05 09:00
MHDA- 2006/02/04 09:00
CRDT- 2005/07/05 09:00
PHST- 2005/01/20 00:00 [received]
PHST- 2005/06/06 00:00 [accepted]
PHST- 2005/07/05 09:00 [pubmed]
PHST- 2006/02/04 09:00 [medline]
PHST- 2005/07/05 09:00 [entrez]
AID - 10.1007/s00134-005-2707-0 [doi]
PST - ppublish
SO  - Intensive Care Med. 2005 Aug;31(8):1101-8. doi: 10.1007/s00134-005-2707-0. Epub 
      2005 Jul 2.